

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

To The Board of Directors of Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended 30 September, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities listed in Annexure A.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Deloitte Haskins & Sells LLP

6. The consolidated unaudited financial results includes the interim financial information/ financial results of four subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total assets of Rs. 190 million as at 30 September, 2021 and, total revenue of Rs. 56 million and Rs. 106 million for the quarter and six months ended 30 September, 2021 respectively, total (loss) after tax of Rs. (5) million and Rs. (5) million for the quarter and six months ended 30 September, 2021 respectively and total comprehensive (loss) of Rs. (5) million and Rs. (5) million for the quarter and six months ended 30 September, 2021 respectively and net cash flows (net) of Rs. (3) million for the six months ended 30 September, 2021, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information/ financial results certified by the Management.

For Deloitte Haskins & Sells LLP

Chartered Accountants

(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal

Partner

(Membership No. 87104)

(UDIN: 21087104AAAAGP8130)

Place: New Delhi

Date: 26 October, 2021

Deloitte Haskins & Sells LLP

Annexure A

List of entities consolidated

a) **Parent Company:** Dr. Lal PathLabs Limited

b) **Subsidiaries held directly**

S. No.	Name of the Entity
1	Paliwal Diagnostics Private Limited
2	Paliwal Medicare Private Limited
3	APL Institute of Clinical Laboratory & Research Private Limited
4	Dr. Lal PathLabs Nepal Private Limited
5	Dr. Lal PathLabs Bangladesh Pvt. Ltd.
6	Dr. Lal Ventures Private Limited
7	PathLabs Unifiers Private Limited
8	Dr. Lal PathLabs Kenya Private Limited

c) **Subsidiaries held indirectly**

S. No.	Name of the Entity
1	Centrapath Labs Private Limited
2	APRL PathLabs Private Limited
3	Chanre Laboratory Private Limited (w.e.f 25 January, 2021)





Dr. Lal PathLabs Limited
CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122001, Haryana
Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Financial Results for the quarter and six months ended 30 September, 2021

(Rs. in million except as stated)

Particulars	3 months ended 30 September, 2021	Preceding 3 months ended 30 June, 2021	Corresponding 3 months ended 30 September, 2020	Year to date figures for the current period ended 30 September, 2021	Year to date figures for the pervious period ended 30 September, 2020	Previous year ended 31 March, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income						
(a) Revenue from operations	4,984	6,066	4,319	11,050	6,979	15,813
(b) Other income	143	141	129	284	243	513
Total income	5,127	6,207	4,448	11,334	7,222	16,326
2 Expenses						
(a) Cost of materials consumed	1,244	1,451	1,083	2,695	1,842	3,973
(b) Employee benefits expense	836	864	688	1,700	1,283	2,737
(c) Finance costs	47	46	40	93	77	160
(d) Depreciation and amortisation expense	205	192	195	397	374	772
(e) Fees to collection centers/channel partners	699	921	561	1,620	854	2,043
(f) Other expenses	790	940	715	1,730	1,245	2,697
Total expenses	3,821	4,414	3,282	8,235	5,675	12,382
3 Profit before tax	1,306	1,793	1,166	3,099	1,547	3,944
4 Tax expense						
(a) Current tax	344	521	308	865	429	1,021
(b) Deferred tax	(1)	(65)	(13)	(66)	(37)	(42)
Total tax expense	343	456	295	799	392	979
5 Profit for the period (A)	963	1,337	871	2,300	1,155	2,965
6 Other comprehensive income						
Items that will not be reclassified to profit or loss						
-Remeasurement of the defined benefit obligations	(28)	(2)	13	(30)	1	(9)
-Income tax in relation to the items that will not be reclassified to profit or loss	8	1	(3)	9	-	2
Items that may be reclassified to profit or loss						
-Exchange differences on translation of foreign operations	-	-	(1)	-	(1)	(1)
Total other comprehensive income/ (loss) (B)	(20)	(1)	9	(21)	-	(8)
7 Total comprehensive income (A+B)	943	1,336	880	2,279	1,155	2,957
Profit for the period attributable to:						
Owners of the Company	950	1,312	853	2,262	1,137	2,916
Non-controlling interest	13	25	18	38	18	49
	963	1,337	871	2,300	1,155	2,965
Other comprehensive income for the period attributable to:						
Owners of the Company	(20)	(1)	9	(21)	-	(8)
Non-controlling interest	-	-	-	-	-	-
	(20)	(1)	9	(21)	-	(8)
Total comprehensive income for the period attributable to:						
Owners of the Company	931	1,311	862	2,242	1,137	2,908
Non-controlling interest	12	25	18	37	18	49
	943	1,336	880	2,279	1,155	2,957
8 Paid-up equity share capital (Face value of Rs. 10 per share)	833	833	833	833	833	833
9 Other equity						11,617
10 Earnings per share (Rs.)						
(Face value of Rs. 10 per share)(not annualised)						
-Basic	11.49	15.87	10.34	27.38	13.79	35.33
-Diluted	11.45	15.84	10.31	27.27	13.75	35.25

Dr. Lal PathLabs Limited

Notes:

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 26 October, 2021. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended September 30, 2021 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iv. The results of the current quarter and six months ended 30 September 2021, are not strictly comparable with the results of quarter ended 30 June, 2021, quarter and six months ended 30 September, 2020 due to resurgent wave of COVID-19 in quarter ended 30 June, 2021, and nationwide lockdown in the corresponding previous six month period.
- v. The Board of Directors of the Parent Company had approved the first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021 which has been paid during the quarter ended September 30, 2021.
- vi. The Board of Directors of the subsidiaries, Paliwal Medicare Private Limited (PMPL) and Paliwal Diagnostics Private Limited (PDPL) in their meetings held on 25 October, 2021 and 25 October, 2021 respectively have approved the "Scheme of Amalgamation" of PMPL with PDPL w.e.f. 1 April, 2021, the appointed date. As per the said scheme, the undertaking of PMPL shall stand transferred to and vested in PDPL on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders of the respective companies, National Company Law Tribunal and other statutory approvals.
- vii. The Board of Directors of the Parent Company and one of the subsidiary company's 'APL Institute of Clinical Laboratory & Research Private Limited' ("APL"), in their respective meetings held on 3 February, 2020 have approved the "Scheme of Amalgamation" of APL with the Parent Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Parent Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the National Company Law Tribunal and other statutory approvals.
- viii. The Board of Directors of the Group, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Group is in the process of assessing the impact of the relevant provisions.
- x. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'g) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram

Date: 26 October, 2021

Dr. Lal PathLabs Limited
Statement of Consolidated Assets and Liabilities

(Rs. in millions except as stated)

Particulars	As at	As at
	30 September, 2021	31 March, 2021
	(Unaudited)	(Audited)
Assets		
1 Non-current assets		
(a) Property, plant and equipment	1,714	1,576
(b) Capital work-in-progress	62	61
(c) Right-of-use assets	1,480	1,483
(d) Goodwill	854	854
(e) Other intangible assets	549	560
(f) Intangible assets under development	7	35
(g) Financial assets		
(i) Loans	-	1
(ii) Other financial assets	185	68
(h) Non-current tax assets (net)	221	229
(i) Deferred tax assets (net)	372	280
(j) Other non-current assets	28	15
Total non-current assets	5,472	5,162
2. Current assets		
(a) Inventories	552	426
(b) Financial assets		
(i) Investments	1,280	593
(ii) Trade receivables	673	667
(iii) Cash and cash equivalents	2,652	2,443
(iv) Bank balances other than (iii) above	7,326	6,817
(v) Loans	9	9
(vi) Other financial assets	383	379
(c) Other current assets	213	117
Total current assets	13,088	11,451
Total assets	18,560	16,613
Equity and liabilities		
1. Equity		
(a) Equity share capital	833	833
(b) Other equity	12,880	11,617
Equity attributable to the owners of the Company	13,713	12,450
Non-controlling interest	338	310
Total equity	14,051	12,760
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	1	1
(ii) Lease liabilities	1,126	1,102
(b) Deferred tax liabilities (net)	24	7
Total non-current liabilities	1,151	1,110
Current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	413	402
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises; and	59	76
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,630	1,365
Sub-total	1,689	1,441
(iii) Other financial liabilities	418	441
(b) Provisions	240	172
(c) Current tax liabilities (net)	321	50
(d) Other current liabilities	277	237
Total current liabilities	3,358	2,743
Total liabilities	4,509	3,853
Total equity and liabilities	18,560	16,613

Dr. Lal PathLabs Limited
Consolidated Cash Flow Statement

(Rs. in millions except as stated)

Particulars	Year to date figures for the current period ended 30 September, 2021	Year to date figures for the previous period ended 30 September, 2020
	(Unaudited)	(Unaudited)
Cash flows from operating activities		
Profit for the year	2,300	1,155
Adjustments for :		
Tax expense	799	392
Interest income	(266)	(207)
Gain on sale or fair valuation of investments	(15)	(28)
Surrender value of keyman insurance policy	(2)	(3)
Expense recognised in respect of employee share based compensation	177	100
Finance cost	93	77
Depreciation and amortisation expense	397	374
Provision for impairment of trade receivables and advances	10	28
Bad debts and advances written off (net)	-	4
Security deposits amortisation	4	3
Remeasurement of the defined benefit obligation	(30)	1
Exchange differences on translation of foreign operations	-	(1)
Operating profit before working capital changes	3,467	1,895
Adjustment for (Increase)/decrease in operating assets:		
(Increase)/decrease in inventories	(126)	102
(Increase) in trade receivables	(16)	(151)
Decrease in loans	1	3
(Increase) in other financial assets	(23)	(4)
(Increase)/decrease in other assets	(96)	22
Adjustment for increase/(decrease) in operating liabilities:		
Increase in trade payables	248	145
Increase in other financial liabilities	21	8
(Decrease)/increase in provisions	68	(6)
Increase in other liabilities	41	22
Cash generated from operations	3,585	2,036
Income taxes paid	(586)	(382)
Net cash generated by operating activities (a)	2,999	1,654
Cash flows from investing activities		
Payments for purchase of property, plant and equipment	(329)	(173)
Proceeds from disposal of property, plant and equipment	-	1
Payments for purchase of other intangible assets	(15)	(49)
Interest received	268	240
Payments for business purchase on slump sale basis*	(41)	(13)
Payments for purchase of investments in mutual funds	(2,143)	(2,311)
Proceeds from sale of investments in mutual funds	1,470	2,765
Bank deposits placed with the banks	(5,208)	(5,922)
Bank deposits with banks encashed	4,595	3,301
Net cash used in investing activities (b)	(1,403)	(2,161)
Cash flows from financing activities		
Proceeds from exercise of share options	1	1
Proceeds from issue of preference shares	-	1
Interest paid	(5)	-
Repayment of lease liability	(60)	(117)
Interest paid on lease liability	(156)	(75)
Dividend paid on equity shares	(1,167)	-
Net cash used in financing activities (c)	(1,387)	(190)
Net increase in cash and cash equivalents (a+b+c)	209	(697)
Cash and cash equivalents at the beginning of the year	2,443	1,967
Cash and cash equivalents at the end of the year	2,652	1,270
Components of cash and cash equivalents		
Cash on hand	13	17
Balance with scheduled banks:		
- on current accounts	121	101
- on cash credit accounts	106	30
- deposits with maturity of less than 3 months	2,412	1,122
Cash and cash equivalents in Cash Flow Statement	2,652	1,270
*Value of assets and liabilities acquired on business purchase through slump sale have been included in movement of respective assets and liabilities		

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

To The Board of Directors of Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the quarter and six months ended 30 September, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**

Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Jitendra Agarwal
(Partner)

(Membership No. 87104)
(UDIN: 21087104AAAAGO1595)

Place: New Delhi
Date: 26 October, 2021

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Standalone Unaudited Financial Results for the quarter and six months ended 30 September, 2021

(Rs. In million except as stated)

Particulars	3 months ended 30 September, 2021	Preceding 3 months ended 30 June, 2021	Corresponding 3 months ended 30 September, 2020	Year to date figures for the current period ended 30 September, 2021	Year to date figures for the previous period ended 30 September, 2020	Previous year ended 31 March, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income						
(a) Revenue from operations	4,704	5,649	4,043	10,353	6,593	14,905
(b) Other income	153	135	125	288	236	513
Total income	4,857	5,784	4,168	10,641	6,829	15,418
2 Expenses						
(a) Cost of materials consumed	1,179	1,337	1,016	2,516	1,746	3,739
(b) Employee benefits expense	781	808	646	1,589	1,209	2,574
(c) Finance costs	43	44	37	87	72	148
(d) Depreciation and amortisation expense	181	168	177	349	341	698
(e) Fees to collection centers/channel partners	685	900	553	1,585	841	2,007
(f) Other expenses	729	875	671	1,604	1,167	2,511
Total expenses	3,598	4,132	3,100	7,730	5,376	11,677
3 Profit before tax	1,259	1,652	1,068	2,911	1,453	3,741
4 Tax expense						
(a) Current tax	326	490	295	816	414	985
(b) Deferred tax	(6)	(71)	(26)	(77)	(48)	(45)
Total tax expense	320	419	269	739	366	940
5 Profit for the period (A)	939	1,233	799	2,172	1,087	2,801
6 Other comprehensive income						
Items that will not be reclassified to profit or loss	(28)	(2)	14	(30)	2	(9)
-Remeasurement of the defined benefit obligations						
-Income tax in relation to the items that will not be reclassified to profit or loss	8	1	(4)	9	(1)	2
Total other comprehensive income/(loss) (B)	(20)	(1)	10	(21)	1	(7)
7 Total comprehensive income (A+B)	919	1,232	809	2,151	1,088	2,794
8 Paid-up equity share capital (Face value of Rs. 10 per share)	833	833	833	833	833	833
9 Other equity						11,338
10 Earnings per share (Rs.)						
(Face value of Rs. 10 per share) (not annualised)						
- Basic	11.36	14.93	9.68	26.28	13.18	33.93
- Diluted	11.31	14.89	9.65	26.18	13.14	33.85

Dr. Lal PathLabs Limited

Notes:

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 26 October, 2021. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended 30 September, 2021 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iii. During the six months ended 30 September, 2021, the Company has made a further investment of INR 45 million in its wholly owned subsidiary, PathLabs Unifiers Private Limited, through subscription of additional equity shares.
- iv. Subsequent to the quarter and six months ended 30 September, 2021 the Company has made a further investment of INR 1 million (KES 1.48 million) in its wholly owned subsidiary, Dr. Lal PathLabs Kenya Private Limited, through subscription of additional equity shares.
- v. The results of the current quarter and six months ended 30 September 2021, are not strictly comparable with the results of quarter ended 30 June, 2021, quarter and six months ended 30 September, 2020 due to resurgent wave of COVID-19 in quarter ended 30 June, 2021 and nationwide lockdown in the corresponding previous six month period.
- vi. The Board of Directors in their meeting held on 3 February, 2020 had approved the "Scheme of Amalgamation" of "APL Institute of Clinical Laboratory & Research Private Limiter (APL) with the Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme, the undertaking of APL shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the National Company Law Tribunal and other statutory approvals.
- vii. The Board of Directors of the Company had approved the first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021 which has been paid during the quarter ended September 30, 2021.
- viii. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Company is in the process of assessing the impact of the relevant provisions.
- x. Refer Annexure A for Statement of standalone Assets and Liabilities.

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited


(Hon'ble) Brig. Dr. Arvind Lal
Executive Chairman

Place: Gurugram
Date: 26 October, 2021

Dr. Lal PathLabs Limited		
Statement of Standalone Assets and liabilities		
(Rs. in millions except as stated)		
Particulars	As at 30 September, 2021	As at 31 March, 2021
	(Unaudited)	(Audited)
Assets		
1. Non-current assets		
(a) Property, plant and equipment	1,572	1,433
(b) Capital work-in-progress	56	55
(c) Right-of-use assets	1,403	1,399
(d) Goodwill	11	11
(e) Other intangible assets	166	158
(f) Intangible assets under development	7	35
(g) Financial assets		
(i) Investments	1,249	1,204
(ii) Loans	-	1
(iii) Other financial assets	183	54
(h) Non-current tax assets (net)	186	205
(i) Deferred tax assets (net)	354	269
(j) Other non-current assets	22	14
Total non-current assets	5,209	4,838
2. Current assets		
(a) Inventories	490	389
(b) Financial assets		
(i) Investments	1,186	502
(ii) Trade receivables	654	635
(iii) Cash and cash equivalents	2,426	2,317
(iv) Bank balances other than (iii) above	7,041	6,570
(v) Loans	8	8
(vi) Other financial assets	361	365
(c) Other current assets	202	107
Total current assets	12,368	10,893
Total assets	17,577	15,731
Equity and liabilities		
1. Equity		
(a) Equity share capital	833	833
(b) Other equity	12,509	11,338
Total equity	13,342	12,171
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	1,067	1,037
Total non-current liabilities	1,067	1,037
Current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	387	376
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	57	71
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,555	1,285
sub-total	1,612	1,356
(iii) Other financial liabilities	382	363
(b) Provisions	222	159
(c) Current tax liabilities (net)	306	49
(d) Other current liabilities	259	220
Total current liabilities	3,168	2,523
Total liabilities	4,235	3,560
Total equity and liabilities	17,577	15,731

Dr. Lal PathLabs Limited		
Standalone Cash Flow Statement		
(Rs. in millions except as stated)		
Particulars	Year to date figures for the current period ended 30 September, 2021	Year to date figures for the previous period ended 30 September, 2020
	(Unaudited)	(Audited)
Cash flows from operating activities		
Profit for the period	2,172	1,087
Adjustments for :		
Tax expense	739	366
Interest income	(256)	(201)
Dividend income from a subsidiary company	(16)	-
Gain on sale or fair valuation of investments	(13)	(27)
Surrender value of keyman insurance policy	(2)	(3)
Expense recognised in respect of employee share based compensation	177	100
Finance cost	87	72
Depreciation and amortisation expense	349	341
Provision for impairment of trade receivables and advances	6	25
Bad debts and advances written off (net)	(1)	3
Security deposits amortisation	5	3
Remeasurement of the defined benefit obligation	(30)	2
Operating profit before working capital and other changes	3,217	1,768
Changes in working capital:		
Adjustment for (increase)/decrease in operating assets:		
(Increase)/decrease in inventories	(101)	110
(Increase) in trade receivables	(24)	(116)
Decrease in loans	1	3
(Increase) in other financial assets	(16)	(2)
(Increase)/decrease in other assets	(95)	22
Adjustment for increase/(decrease) in operating liabilities:		
Increase in trade payables	256	121
Increase in other financial liabilities	19	9
Increase/(Decrease) in provisions	64	(9)
Increase in other liabilities	39	23
Cash generated from operations	3,360	1,929
Income taxes paid	(539)	(367)
Net cash generated from operating activities (a)	2,821	1,562
Cash flows from investing activities		
Payments for purchase of property, plant and equipment	(307)	(150)
Proceeds from disposal of property, plant and equipment	-	1
Payments for purchase of other intangible assets	(14)	(49)
Dividend received from a subsidiary company	16	-
Interest received	263	236
Investment in subsidiaries	(45)	(15)
Payments for purchase of investments in mutual funds	(2,116)	(2,219)
Proceeds from sale of investments in mutual funds	1,445	2,715
Bank deposits placed with the banks	(5,131)	(5,904)
Bank deposits with banks encashed	4,543	3,236
Net cash used in investing activities (b)	(1,346)	(2,149)
Cash flows from financing activities		
Proceeds from exercise of share options	1	1
Repayment of lease liability	(122)	(109)
Interest on lease liability	(87)	(72)
Interest paid	(1)	-
Dividend paid on equity shares	(1,157)	-
Net cash used in financing activities (c)	(1,366)	(180)
Net increase/ decrease in cash and cash equivalents (a+b+c)	109	(767)
Cash and cash equivalents at the beginning of the year	2,317	1,892
Cash and cash equivalents at the end of the year	2,426	1,125
Components of cash and cash equivalents		
Cash on hand	11	14
Balance with scheduled banks:		
- on current accounts	69	52
- on cash credit accounts	106	30
- deposits with maturity of less than 3 months	2,240	1,029
Total cash and cash equivalents in Cash Flow Statement	2,426	1,125